Wegovy (semaglutide 2.4 mg) is a prescription-only weight management medicine licensed by the MHRA for adults with obesity or overweight with weight-related health conditions. As a glucagon-like peptide-1 (GLP-1) receptor agonist administered as a once-weekly injection, Wegovy works by reducing appetite, slowing gastric emptying, and decreasing caloric intake. Understanding the cost of Wegovy is essential for patients considering this treatment, as pricing varies significantly between NHS and private prescriptions. This article examines the factors affecting Wegovy cost in the UK, compares NHS versus private access, explores alternative treatments, and provides guidance on budgeting for this medication as part of a comprehensive weight management programme.

What Is Wegovy and How Does It Work?

Wegovy (semaglutide 2.4 mg) is a prescription-only medicine licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related health condition. It belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for type 2 diabetes management but now also used for weight management.^[1][15]

The mechanism of action centres on mimicking the naturally occurring hormone GLP-1, which is released from the intestine after eating. Wegovy works by:

• Slowing gastric emptying, which prolongs the feeling of fullness after meals

• Reducing appetite by acting on receptors in the brain that regulate hunger and satiety

• Decreasing overall caloric intake as patients experience reduced food cravings

• Affecting hormonal regulation related to blood glucose control

Administered as a once-weekly subcutaneous injection, Wegovy is gradually titrated over 16–20 weeks to the maintenance dose of 2.4 mg to minimise gastrointestinal side effects. Clinical trials (STEP programme) have demonstrated that patients using Wegovy alongside lifestyle interventions (diet and exercise) can achieve an average weight loss of 10–15% of their initial body weight over 68 weeks.^[3][4]

It is important to note that Wegovy is not a standalone solution. NICE guidance emphasises that semaglutide should be prescribed as part of a comprehensive weight management programme that includes dietary modification, increased physical activity, and behavioural support. Treatment response should be assessed after 16 weeks at the maintenance dose, with continuation only if at least 5% weight loss has been achieved. While the medication may be used long-term, NHS provision is typically limited to up to 2 years in specialist weight management services, and evidence beyond this timeframe is limited.^[8][9] Discontinuation often results in weight regain, highlighting the chronic nature of obesity as a medical condition requiring sustained intervention.

Patients should report any suspected side effects to their healthcare professional or directly to the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Factors That Affect the Price of Wegovy

The cost of Wegovy in the UK varies considerably depending on several key factors, making it essential for patients to understand what influences pricing before commencing treatment.

Prescription route is the primary determinant. NHS prescriptions follow standardised pricing structures, whereas private prescriptions reflect market rates set by individual pharmacies and clinics. Private costs typically range from approximately £200 to £300 per month for the maintenance dose, though introductory doses during the titration phase may cost slightly less due to lower drug quantities. These figures are indicative and can vary significantly.

Supply and demand dynamics have significantly impacted Wegovy availability and pricing since its UK launch. Periodic shortages driven by global demand have led some private providers to implement waiting lists or adjust pricing. The manufacturer, Novo Nordisk, has worked to increase production capacity, but supply constraints have historically created price volatility in the private market.

Clinic or pharmacy markup varies substantially. Online prescribing services, high-street pharmacies, private weight management clinics, and hospital-based services each apply different pricing models. Some providers bundle the medication cost with consultation fees, monitoring appointments, and nutritional support, whilst others charge separately for these services. Patients should request transparent, itemised pricing to compare true costs effectively.

Dosage and treatment duration also influence overall expenditure. The titration schedule requires four different dose strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg) before reaching the 2.4 mg maintenance dose. Treatment duration varies by individual response and setting. In NHS specialist services, treatment is typically commissioned for up to 2 years in line with NICE guidance, while private treatment length depends on clinical response, tolerability and patient preference.

Insurance coverage remains limited. Most private health insurance policies in the UK exclude weight management medications, though some employers or enhanced policies may provide partial reimbursement. Patients should verify specific coverage details directly with their insurer before commencing treatment.

Alternatives to Wegovy and Cost Comparisons

Several alternatives to Wegovy exist for weight management, each with distinct mechanisms, efficacy profiles, and cost implications.

Saxenda (liraglutide 3 mg) is another GLP-1 receptor agonist licensed for weight management. Unlike Wegovy's weekly injection, Saxenda requires daily subcutaneous administration, which some patients find less convenient. Clinical trials show Saxenda produces average weight loss of 5–10%, somewhat less than Wegovy's 10–15%. Private costs are comparable, typically ranging from approximately £150–£250 per month, though the daily injection requirement means patients use medication more frequently. NHS access to Saxenda is also via specialist weight management services under NICE guidance (TA664) with similar eligibility criteria to Wegovy.^[11][12]

Orlistat (available as prescription-strength Xenical 120 mg or over-the-counter Alli 60 mg) works by inhibiting pancreatic lipase, reducing dietary fat absorption by approximately 30%.^[13] It costs significantly less—approximately £40–£80 per month privately—but produces more modest weight loss (3–5% on average) and frequently causes gastrointestinal side effects including oily stools, faecal urgency, and flatulence.^[13] NICE includes orlistat as an option for weight management where appropriate, particularly when other treatments are unsuitable.

Zepbound/Mounjaro (tirzepatide), recently authorised in the UK for weight management, is a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Evidence suggests it may produce weight loss exceeding that of Wegovy, with some patients losing 15–20% of body weight.^[16][17] Private costs are expected to be similar to or higher than Wegovy, though NHS commissioning arrangements are still developing.

Lifestyle interventions alone—including structured diet programmes, commercial weight management services, and behavioural therapy—represent the foundation of weight management. Whilst medication can enhance outcomes, NICE emphasises that sustainable weight loss requires long-term lifestyle modification regardless of pharmacological support.

Wegovy Cost in the UK: NHS vs Private Prescriptions

Understanding the distinction between NHS and private access to Wegovy is crucial for patients considering this treatment option.

NHS availability of Wegovy is currently extremely limited. In March 2023, NICE published guidance (TA875) recommending semaglutide 2.4 mg for weight management in adults with at least one weight-related comorbidity and a BMI of ≥35 kg/m² (or ≥32.5 kg/m² for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family backgrounds). However, NHS England has implemented a phased rollout due to supply constraints and capacity limitations within specialist weight management services.

NHS provision focuses on patients with the highest clinical need through specialist weight management services in secondary care. Wegovy is not routinely initiated in primary care under current NHS commissioning arrangements. Patients meeting NICE criteria should discuss referral options with their GP, though waiting times for specialist services vary considerably by location. When prescribed via the NHS, patients pay the standard prescription charge (currently £9.90 per item in England, free in Scotland, Wales, and Northern Ireland), representing exceptional value compared to private costs.

Private prescriptions offer more immediate access but at substantial cost. Patients can access Wegovy through:

• Online prescribing services

• Private GP practices and weight management clinics

• Hospital-based private services

Total monthly costs typically include:

• Medication: approximately £200–£300

• Initial consultation: £50–£150

• Follow-up appointments: £30–£80 per session

• Monitoring investigations (blood tests as clinically indicated): £50–£150

Patients should budget for approximately £2,500–£4,000 annually for private Wegovy treatment including all associated costs, though prices vary widely. Reputable providers require baseline assessment, regular monitoring, and evidence of lifestyle modification before prescribing, in line with General Medical Council prescribing guidance and Care Quality Commission standards. Patients should be cautious of services offering Wegovy without proper medical assessment, as this raises safety concerns.

Frequently Asked Questions